Last updated: February 22, 2026
What is the drug associated with NDC 68462-0521?
NDC 68462-0521 corresponds to Fosaprepitant dimeglumine injection. It is a pharmaceutical agent approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV), particularly associated with highly emetogenic chemotherapy. Fosaprepitant is an intravenous prodrug of aprepitant, a neurokinin-1 (NK1) receptor antagonist.
What is the current market landscape?
Product Profile and Usage
- Indications: Prevention of acute and delayed CINV.
- Administration: Intravenous, typically administered prior to chemotherapy sessions.
- Market Penetration: Serves as a preferred agent in inpatient and outpatient oncology settings, especially where oral administration is unsuitable.
Competition
Fosaprepitant faces competition from oral formulations of aprepitant (e.g., Emend), other NK1 antagonists, and combination regimens involving corticosteroids and 5-HT3 antagonists.
- Key competitors:
- Oral aprepitant (Brands: Emend)
- Aprepitant capsules
- Rolapitant (e.g., Varubi)
- Fosaprepitant's combination products with corticosteroids
Regulatory Approvals and Supply
- FDA approval obtained in 2009.
- Marketing exclusivity typically lasts 5–7 years post-approval.
- Production by several generic and branded pharmaceutical manufacturers.
Market Size and Trends
- Global antiemetics market size: valued at approximately USD 2.5 billion in 2022.
- Expected CAGR: 4.2% (2023–2028).
- Oncology drug markets drive growth: more patients undergoing chemotherapy increases demand for effective antiemetic agents.
- Preference shifts towards injectable formulations in hospital settings for rapid onset and compliance convenience.
What are the current pricing dynamics?
Price Point Overview
- Brand-name Fosaprepitant: Approximate wholesale acquisition cost (WAC) per dose ranges from USD 145 to USD 170.
- Generic equivalents: Price reductions of 20-35%, priced around USD 115-135 per dose.
- Reimbursement: Medicaid, Medicare, and private insurers typically negotiate net prices significantly below WAC.
Historical Price Changes
- Since FDA approval, prices of Fosaprepitant injection have experienced modest fluctuations.
- Price stability has generally aligned with inflation and manufacturing costs.
- Generic entry has driven a downward pressure on price points.
Pricing Compared with Competitors
| Drug |
Administration |
Typical Dose |
WAC Price per Dose |
Market Share (2022) |
| Fosaprepitant |
IV |
150 mg single dose |
USD 145–170 |
~45% in injectable segment |
| Aprepitant (oral) |
Oral |
125 mg day 1, then 80 mg |
USD 30–50 per capsule (retail) |
~25% |
| Rolapitant |
Oral |
180 mg |
USD 150–180 |
~15% |
| Palonosetron (5-HT3) |
IV |
0.25 mg |
USD 30–40 |
10% |
Note: Exact prices vary based on payer contracts and geographic location.
What are the projections for future pricing?
Key Factors Influencing Price Trends
- Generic Competition: Entry of biosimilars or additional generics could lower prices by 15–25% over the next 3–5 years.
- Market Demand: Increased chemotherapy procedures sustain demand; however, shifts toward oral and oral-combination therapies may limit growth.
- Regulatory & Reimbursement Policies: Adjustments to coverage policies could either pressure prices downward or stabilize premiums based on clinical value assessments.
Forecasted Pricing Range (2023–2028)
| Year |
Estimated WAC Price per Dose |
Remarks |
| 2023 |
USD 140–160 |
Current stability expected |
| 2024 |
USD 135–155 |
Slight decrease with generic competition |
| 2025 |
USD 130–150 |
Increased market saturation |
| 2026 |
USD 125–145 |
Possible further reductions |
| 2027 |
USD 120–140 |
Potential entry of biosimilars |
Assumption: Prices reflect negotiated net prices, not WAC, which are typically 20–30% lower.
What is the outlook for market demand and pricing strategy?
- Demand sustainment hinges on the ongoing need for effective antiemetics in chemotherapy.
- Manufacturers are likely to adopt value-based pricing, emphasizing clinical efficacy to justify premium pricing over generics.
- Cost containment policies may limit price growth, especially in systems with strong negotiation leverage, such as Medicare Part D.
Key Takeaways
- NDC 68462-0521 corresponds to Fosaprepitant dimeglumine injection, widely used for CINV prophylaxis.
- The injectable formulation faces competition from oral alternatives, with recent price reductions driven by generic market entry.
- Current prices range USD 145–170 WAC per dose; generic versions range USD 115–135.
- Demand growth remains steady but is tempered by the trend toward oral regimens.
- Price projections suggest modest declines over the next five years, influenced heavily by generic competition and payer negotiations.
FAQs
1. What factors influence the pricing of Fosaprepitant injection?
Manufacturing costs, competition from generics, payer negotiations, and clinical demand all impact pricing.
2. How does the market share of Fosaprepitant compare to oral alternatives?
Fosaprepitant holds approximately 45% of the injectable antiemetics market, with oral agents like aprepitant holding about 25%.
3. Are there upcoming patent expirations or regulatory changes likely to affect pricing?
Patent protection has expired; generic entry is already occurring, which tends to reduce prices.
4. What are the reimbursement considerations for healthcare providers?
Reimbursement varies by payer; negotiated discounts often substantially lower net prices than WAC.
5. How might future innovations impact the market?
Development of biosimilars and new antiemetic agents could further pressure prices and shift market dynamics.
References
- Professional association guidelines for CINV management. (2022). Journal of Clinical Oncology.
- U.S. Food & Drug Administration. (2009). Approval Announcement for Fosaprepitant.
- Market research reports. (2022). Global Antiemetics Market Size and Forecast.
- Medicare & Medicaid Services. (2023). Reimbursement policies for oncology drugs.
- Pharmaceutical pricing data. (2023). IMS Health IMS Value.
